Indeed, CBZ has been reported to significantly reduce spontaneous electrographic epileptic discharges in APP/PS1 transgenic mice and to improve cognitive impairment in APP/PS1ΔE mice by reducing Aβ plaque burden [115]. Here, APP is linked to Cognitive impairment.